BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jan AS, Hosing C, Aung F, Yeh J. Approaching treatment of transplant-associated thrombotic Microangiopathy from two directions with Eculizumab and transitioning from Tacrolimus to Sirolimus. Transfusion 2019;59:3519-24. [PMID: 31587288 DOI: 10.1111/trf.15534] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Jarmoliński T, Rosa M, Puziewicz-Zmonarska A, Kałwak K. Short Course of Eculizumab May Be Effective in Dialysis-Dependent Transplantation-Associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation: A Case Report. Transplant Proc 2020;52:2544-7. [PMID: 32917392 DOI: 10.1016/j.transproceed.2020.08.040] [Reference Citation Analysis]
2 Milone G, Bellofiore C, Leotta S, Milone GA, Cupri A, Duminuco A, Garibaldi B, Palumbo G. Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology. J Clin Med 2022;11:623. [PMID: 35160072 DOI: 10.3390/jcm11030623] [Reference Citation Analysis]
3 Yang LP, Liu X, Zhang XH. [Advances in the diagnosis and management of transplant-associated thrombotic microangiopathy]. Zhonghua Xue Ye Xue Za Zhi 2021;42:693-9. [PMID: 34547882 DOI: 10.3760/cma.j.issn.0253-2727.2021.08.018] [Reference Citation Analysis]
4 Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC, Wallace G, Nelson A, Bleesing J, Chima RS, Hirsch R, Ryan TD, Benoit S, Mizuno K, Warren M, Davies SM. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood 2020;135:1049-57. [PMID: 31932840 DOI: 10.1182/blood.2019004218] [Cited by in Crossref: 14] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
5 Hematopoietic Stem Cell Application Group, Chinese Society of Hematology, Chinese Medical Association. [Chinese consensus on the diagnosis and management of transplant-associated thrombotic microangiopathy (2021)]. Zhonghua Xue Ye Xue Za Zhi 2021;42:177-84. [PMID: 33910301 DOI: 10.3760/cma.j.issn.0253-2727.2021.03.001] [Reference Citation Analysis]
6 Kanunnikov MM, Rakhmanova ZZ, Levkovsky NV, Vafina AI, Goloshapov OV, Shchegoleva TS, Vlasova JJ, Paina OV, Morozova EV, S Zubarovskaya L, Kulagin AD, S Moiseev I. Conversion from calcineurin inhibitors to sirolimus in transplant-associated thrombotic microangiopathy. Clin Transplant 2021;35:e14180. [PMID: 33258122 DOI: 10.1111/ctr.14180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Arrabi L, Jan A, Hosing C, Milton DR, Yeh J. Transitioning tacrolimus to sirolimus in allogeneic hematopoietic cell transplantation. Eur J Haematol 2021;107:634-41. [PMID: 34431142 DOI: 10.1111/ejh.13701] [Reference Citation Analysis]
8 Zhang Z, Wang H, Qi J, Tang Y, Cai C, Zhou M, Pan T, Wu D, Han Y. Acute graft-versus-host disease increase risk and accuracy in prediction model of transplantation-associated thrombotic microangiopathy in patients with myelodysplastic syndrome. Ann Hematol 2022. [PMID: 35357522 DOI: 10.1007/s00277-022-04820-z] [Reference Citation Analysis]
9 Gallan AJ, Chang A. A New Paradigm for Renal Thrombotic Microangiopathy. Semin Diagn Pathol 2020;37:121-6. [PMID: 32085935 DOI: 10.1053/j.semdp.2020.01.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]